News Archive
Previous Article   |   Next Article
Regulatory Notice, RNS Announcements | 1 Apr 2015

Directors’ Shareholding

London: Wednesday, 1 April 2015: Chi-Med received notifications on 1 April 2015 that the following Directors have purchased ordinary shares of US$1.00 each in Chi-Med (the “Shares”) as follows:-

Director

Date of purchase

Number of Shares
purchased

Purchase
price

Beneficial interest in
Shares following purchases

Number
of Shares

% of total issued
share capital

Simon To
(Executive Director
and Chairman)

30 March 2015

1 April 2015

13,000

15,000

GBP13.00

GBP13.65

69,000

0.13%

Edith Shih
(Non-executive Director
and Company Secretary)

30 March 2015

1 April 2015

13,000

15,000

GBP13.00

GBP13.65

48,000

0.09%

Ends

Enquiries

Chi-Med
Telephone: +852 2121 8200
Christian Hogg, CEO

Panmure Gordon (UK) Limited
Telephone: +44 20 7886 2500
Richard Gray
Andrew Potts

Citigate Dewe Rogerson
Telephone: +44 20 7638 9571
Anthony Carlisle Mobile: +44 7973 611 888
David Dible Mobile: +44 7967 566 919

About Chi-Med
Chi-Med is a China-based healthcare group focused on researching, developing, manufacturing and selling pharmaceuticals and health-related consumer products. Its Drug R&D Division focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases. Its China Healthcare Division manufactures, markets and distributes prescription and over-the-counter pharmaceuticals in China. Its emerging Consumer Products Division focuses on organic and natural consumer products in Asia.

Chi-Med is majority owned by the multinational conglomerate Hutchison Whampoa Limited (SEHK:13). For more information, please visit: www.chi-med.com.